Search

Your search keyword '"Morrow, AT"' showing total 701 results
Start Over Author "Morrow, AT" Journal circulation
701 results on '"Morrow, AT"'

2. Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation

Author

Patel, Siddharth M., Braunwald, Eugene, Steffel, Jan, Boriani, Giuseppe, Palazzolo, Michael G., Antman, Elliott M., Bohula, Erin A., Carnicelli, Anthony P., Connolly, Stuart J., Eikelboom, John W., Gencer, Baris, Granger, Christopher B., Morrow, David A., Patel, Manesh R., Wallentin, Lars, Ruff, Christian T., and Giugliano, Robert P.

Published
2024
Full Text
View/download PDF

3. Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial

Author

Sidik, Novalia P., Stanley, Bethany, Sykes, Robert, Morrow, Andrew J., Bradley, Conor P., McDermott, Michael, Ford, Thomas J., Roditi, Giles, Hargreaves, Allister, Stobo, David, Adams, Jacqueline, Byrne, John, Mahrous, Ahmed, Young, Robin, Carrick, David, McGeoch, Ross, Corcoran, David, Lang, Ninian N., Heggie, Robert, Wu, Olivia, McEntegart, Margaret B., McConnachie, Alex, and Berry, Colin

Published
2024
Full Text
View/download PDF

4. Abstract 18221: Interleukin-6 in Patients With HFrEF and the Effect of Dapagliflozin: Insights From DAPA-HF

Author

Docherty, Kieran, Welsh, Paul, Anand, Inder S, Berg, David, de Boer, Rudolf A, Kober, Lars, Kosiborod, Mikhail N, Martinez, Felipe, OMeara, Eileen, Morrow, David, Petrie, Mark, Ponikowski, Piotr, Sabatine, Marc S, Schou, Morten, Sattar, Naveed, Hammarstedt, Ann, Langkilde, Anna Maria, Sjostrand, Mikaela, Solomon, Scott, Jhund, Pardeep S, and McMurray, John J

Published
2023
Full Text
View/download PDF

6. Abstract 16908: CTX310: An Investigational in vivo CRISPR-Based Therapy Efficiently and Durably Reduces ANGPTL3 Protein and Triglyceride Levels in Non-Human Primates After a Single Dose

Author

Morrow, Phuong Khanh, Chen, Yi-Shan, Serwer, Laura, Detwiler, Zachary, Flanagan, Nicole, Koch, Elizabeth, Lei Zhang, Maria, Mu, Michelle, Nguyen, Thao, Sula, Erisa, Thorstensen, Erin, Tomp, Samuel, Urbaez, Kayla, Usadi, Jacob, Wang, Li, Watrud, Kaitlin, Wood, Tess, and Zhang, Xuezhi

Published
2023
Full Text
View/download PDF

11. Abstract 13676: Characteristics and Outcomes of Patients With Clinically Significant Valvular Heart Disease and Cardiogenic Shock Admitted to Cardiac Intensive Care Units

Author

Carnicelli, Anthony P, Miller, Elliott, Chonde, Meshe, Berg, David, Palazzolo, Michael, Aliyev, Nijat, Bohula, Erin A, Hamilton, Madeleine, Keane, Ryan, Kusner, Jonathan, Loriaux, Daniel, Newby, L Kristin K, Patolia, Harsh, Pierce, Jacob, Van Diepen, Sean, Katz, Jason N, and Morrow, David

Published
2023
Full Text
View/download PDF

16. Myocardial Involvement After Hospitalization for COVID-19 Complicated by Troponin Elevation: A Prospective, Multicenter, Observational Study

Author

Artico, Jessica, Shiwani, Hunain, Moon, James C., Gorecka, Miroslawa, McCann, Gerry P., Roditi, Giles, Morrow, Andrew, Mangion, Kenneth, Lukaschuk, Elena, Shanmuganathan, Mayooran, Miller, Christopher A., Chiribiri, Amedeo, Prasad, Sanjay K., Adam, Robert D., Singh, Trisha, Bucciarelli-Ducci, Chiara, Dawson, Dana, Knight, Daniel, Fontana, Marianna, Manisty, Charlotte, Treibel, Thomas A., Levelt, Eylem, Arnold, Ranjit, Macfarlane, Peter W., Young, Robin, McConnachie, Alex, Neubauer, Stefan, Piechnik, Stefan K., Davies, Rhodri H., Ferreira, Vanessa M., Dweck, Marc R., Berry, Colin, Greenwood, John P., Kelly, Bernard, Goreka, Miroslawa, Somers, Kathryn, Byrom-Goulthorp, Roo J., Anderson, Michelle, Britton, Laura, Richards, Fiona, Jones, Laura M., Moss, Alastair, Fisher, Jude, Wormleighton, Joanne, Parke, Kelly, Wright, Rachel, Yeo, Jian, Falconer, Judith, Harries, Valerie, Henderson, Paula, Newby, David, Popescu, Iulia, Zhang, Qiang, Raman, Betty, Channon, Keith, Krasopoulos, Catherine, Nunes, Claudia, Da Silva Rodrigues, Liliana, Nixon, Harriet, Panopoulou, Athanasia, Fletcher, Alison, Manley, Peter, Sykes, Robert, Fallon, Kirsty, Brown, Ammani, Kelly, Laura, McGinley, Christopher, Briscoe, Michael, Woodward, Rosemary, Hopkins, Tracey, McLennan, Evonne, Tynan, Nicola, Dymock, Laura, Swoboda, Peter, Wright, Judith, Exley, Donna, Steeds, Richard, Hutton, Kady, MacDonald, Sonia, Shetye, Abhishek, Orsborne, Christopher, Woodville-Jones, William, Ferguson, Susan, Bratis, Konstantinos, Fairbairn, Timothy, Sionas, Michail, Widdows, Peris, Gee Chew, Pei, Marsden, Christian, Collins, Tom, George, Linsha, Kearney, Lisa, Flett, Andrew, Smith, Simon, Zhenge, Alice, Harvey, Jake, Inacio, Liliana, Hanam-Penfold, Tomas, Gruner, Lucy, Razvi, Yousuf S.K., Crause, Jacolene, Davies, Nina M., Brown, James T., Chaco, Liza, Patel, Rishi, Kotecha, Tushar, Knight, Dan S., Green, Thomas, Ripley, David, Thompson, Maria, Cifra, Ugochi Akerele Elna, Alskaf, Ebraham, Crawley, Richard, Villa, Adriana, Nightingale, Angus K., Wright, Kim, Bonnick, Esther D., Hopkins, Emma, George, Jessy, Joseph, Linta, Cole, Graham, Vimalesvaran, Kavitha, Ali, Nadine, Carr, Caitlin R., Ross, Alexandra A.R., King, Clara, Farzad, Zohreh, Salmi, Sara A., Kirby, Kevin, McDiarmid, Adam, Stevenson, Hannah J., Matsvimbo, Pamela S., Joji, Lency, Fearby, Margaret, Brown, Benjamin, Bunce, Nicholas, Jennings, Robert, Sookhoo, Vennessa, Joshi, Shatabdi, Kanagala, Prathap, Fullalove, Sandra, Toohey, Catherine, Fenlon, Kate, Bellenger, Nicholas, He, Jingzhou, Statton, Sarah, Pamphilon, Nicola, Steele, Anna, Ball, Claire, McGahey, Ann, Balma, Silvia, Wilkes, Lynsey, Lewis, Katy, Walter, Michelle, Ionescu, Adrian, Ninan, Tishi, Richards, Suzanne, Williams, Marie, Alfakih, Khaled, Pilgrim, Samia, Joy, George, and Hussain, Ifza

Published
2023
Full Text
View/download PDF

18. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

Author

Yeoh, Su Ern, Docherty, Kieran F., Campbell, Ross T., Jhund, Pardeep S., Hammarstedt, Ann, Heerspink, Hiddo J.L., Jarolim, Petr, Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Solomon, Scott D., Sjöstrand, Mikaela, Bengtsson, Olof, Greasley, Peter J., Sattar, Naveed, Welsh, Paul, Sabatine, Marc S., Morrow, David A., and McMurray, John J.V.

Published
2023
Full Text
View/download PDF

25. Abstract 10406: Longitudinal Trends in Cardiovascular Complications Among Patients Hospitalized for Covid-19 Infection: A National Multi-Center Analysis

Author

Hall, Eric J, Das, Sandeep R, Ayers, Colby, Bradley, Steven M, Elkind, Mitchell, Hall, Jennifer L, Kolkailah, Ahmed A, Mallya, Pratheek, Morrow, David, Rodriguez, Fatima, Roth, Gregory A, Rutan, Christine, Stevens, Laura, Wang, Tracy Y, Walchok, Jason, Williams, Joseph H, and De Lemos, James A

Published
2022
Full Text
View/download PDF

26. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Author

Carnicelli, Anthony P., Hong, Hwanhee, Connolly, Stuart J., Eikelboom, John, Giugliano, Robert P., Morrow, David A., Patel, Manesh R., Wallentin, Lars, Alexander, John H., Cecilia Bahit, M., Benz, Alexander P., Bohula, Erin A., Chao, Tze-Fan, Dyal, Leanne, Ezekowitz, Michael, A.A. Fox, Keith, Gencer, Baris, Halperin, Jonathan L., Hijazi, Ziad, Hohnloser, Stefan H., Hua, Kaiyuan, Hylek, Elaine, Toda Kato, Eri, Kuder, Julia, Lopes, Renato D., Mahaffey, Kenneth W., Oldgren, Jonas, Piccini, Jonathan P., Ruff, Christian T., Steffel, Jan, Wojdyla, Daniel, and Granger, Christopher B.

Published
2022
Full Text
View/download PDF

27. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial

Author

Berg, David D., Docherty, Kieran F., Sattar, Naveed, Jarolim, Petr, Welsh, Paul, Jhund, Pardeep S., Anand, Inder S., Chopra, Vijay, de Boer, Rudolf A., Kosiborod, Mikhail N., Nicolau, Jose C., O’Meara, Eileen, Schou, Morten, Hammarstedt, Ann, Langkilde, Anna-Maria, Lindholm, Daniel, Sjöstrand, Mikaela, McMurray, John J.V., Sabatine, Marc S., and Morrow, David A.

Published
2022
Full Text
View/download PDF

28. Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial

Author

Sidik, Novalia P., primary, Stanley, Bethany, additional, Sykes, Robert, additional, Morrow, Andrew J., additional, Bradley, Conor P., additional, McDermott, Michael, additional, Ford, Thomas J., additional, Roditi, Giles, additional, Hargreaves, Allister, additional, Stobo, David, additional, Adams, Jacqueline, additional, Byrne, John, additional, Mahrous, Ahmed, additional, Young, Robin, additional, Carrick, David, additional, McGeoch, Ross, additional, Corcoran, David, additional, Lang, Ninian N., additional, Heggie, Robert, additional, Wu, Olivia, additional, McEntegart, Margaret B., additional, McConnachie, Alex, additional, and Berry, Colin, additional

Published
2023
Full Text
View/download PDF

29. Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC)

Author

Waksman, Ron, primary, Pahuja, Mohit, additional, van Diepen, Sean, additional, Proudfoot, Alastair G., additional, Morrow, David, additional, Spitzer, Ernest, additional, Nichol, Graham, additional, Weisfeldt, Myron L., additional, Moscucci, Mauro, additional, Lawler, Patrick R., additional, Mebazaa, Alexandre, additional, Fan, Eddy, additional, Dickert, Neal W., additional, Samsky, Marc, additional, Kormos, Robert, additional, Piña, Ileana L., additional, Zuckerman, Bram, additional, Farb, Andrew, additional, Sapirstein, John S., additional, Simonton, Charles, additional, West, Nick E.J., additional, Damluji, Abdulla A., additional, Gilchrist, Ian C., additional, Zeymer, Uwe, additional, Thiele, Holger, additional, Cutlip, Donald E., additional, Krucoff, Mitchell, additional, and Abraham, William T., additional

Published
2023
Full Text
View/download PDF

30. Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study

Author

Schrage, Benedikt, Becher, Peter Moritz, Bernhardt, Alexander, Bezerra, Hiram, Blankenberg, Stefan, Brunner, Stefan, Colson, Pascal, Cudemus Deseda, Gaston, Dabboura, Salim, Eckner, Dennis, Eden, Matthias, Eitel, Ingo, Frank, Derk, Frey, Norbert, Funamoto, Masaki, Goßling, Alina, Graf, Tobias, Hagl, Christian, Kirchhof, Paulus, Kupka, Danny, Landmesser, Ulf, Lipinski, Jerry, Lopes, Mathew, Majunke, Nicolas, Maniuc, Octavian, McGrath, Daniel, Möbius-Winkler, Sven, Morrow, David A., Mourad, Marc, Noel, Curt, Nordbeck, Peter, Orban, Martin, Pappalardo, Federico, Patel, Sandeep M., Pauschinger, Matthias, Pazzanese, Vittorio, Reichenspurner, Hermann, Sandri, Marcus, Schulze, P. Christian, H.G. Schwinger, Robert, Sinning, Jan-Malte, Aksoy, Adem, Skurk, Carsten, Szczanowicz, Lukasz, Thiele, Holger, Tietz, Franziska, Varshney, Anubodh, Wechsler, Lukas, and Westermann, Dirk

Published
2020
Full Text
View/download PDF

31. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

Author

Erin A. Bohula, David D. Berg, Mathew S. Lopes, Jean M. Connors, Ijlal Babar, Christopher F. Barnett, Sunit-Preet Chaudhry, Amit Chopra, Wilson Ginete, Michael H. Ieong, Jason N. Katz, Edy Y. Kim, Julia F. Kuder, Emilio Mazza, Dalton McLean, Jarrod M. Mosier, Ari Moskowitz, Sabina A. Murphy, Michelle L. O’Donoghue, Jeong-Gun Park, Rajnish Prasad, Christian T. Ruff, Mohamad N. Shahrour, Shashank S. Sinha, Stephen D. Wiviott, Sean Van Diepen, Mark Zainea, Vivian Baird-Zars, Marc S. Sabatine, David A. Morrow, Kyung Ah Im, Retu Saxena, Brandon Wiley, Carina Benson, Roman Delamed, Nedaa Skeik, Ami Chopra, Marc Judson, Scott Beegle, Boris Shkolnik, Anupama Tiwari, Gregory Wu, Abhijit Raval, Emerald Branch, Franz Rischard, Cameron Hypes, Billie Bixby, Christian Bime, Madhan Sundaram, Nancy Sweitzer, Alfredo Vazquez Sandoval, Heath White, Katherine Berg, Shahzad Shaefi, Michael Donnino, Brett Carroll, Michael Ieong, Kimberly Ackerbauer, Jaime Murphy, Ankeet Bhatt, Alexander Blood, Siddharth Patel, Victor Luu, Shraddha Narechania, Austin Lorganger, Robert Plambeck, Ali Nayfeh, Michael Sanley, Michel Del Cor, AJ Hegg, Winston Nara, Michael Snyder, Faisal Khan, Imad Shawa, Joshua Larned, Elias Collado, Mohammed Al Faiyumi, Rajeev Mehta, Sudarshan Komanapalli, Vijayadershan Muppidi, Mehul Desai, Casey Flanagan, Leonard Genovese, Tariq Haddad, Christopher King, Amber Peterson, Thane Htun, Elizabeth Pionk, Nicolas Mouawad, Chintalapudi Kumar, Kevin Nguyen, Majid Mughal, Ryan Malek, Akarsh Parekh, Christopher Provenzano, Melissa Ianitelli, Nicole Prentice-Gaytan, Adam Bykowski, Don Tait, Shelley Schendel, Varun Yalamanchili, Vasim Lala, Victor Hunyadi, Alexander Papolos, Benjamin Kenigsberg, Aarthi Shenoy, Thomas Stuckey, Douglas McQuaid, Praveen Mannam, Jeffrey McClung, Kent Nilsson, Andrew McKown, Jason Wells, David Hotchkin, Marc Jacobs, Wayne Strauss, Rick Balestra, Vikram Sahni, R. Jeffrey Snell, Hussam Suradi, Sarah Sungurlu, Jessica Kuppy, Eileen Gajo, Foster Adams, Abbas Shehadeh, Addi Suleiman, Harish Nandigam, Jihad Slim, Sardar Ijlal Babar, Dipti Baral, Talha Nawaz, Syed Abdullah Waheed, Randy Roth, Subhas Sitaula, Shahid Hayat, Jooby Babu, Jason Caberto, Victor Hsu, Robert Chang, Markian Bochan, Rafael Garcia-Cortes, Hal Skopicki, On Chen, Lauren Pilato, Paul Richman, Alexander Adler, Praveen Sudhindra, Jamie Beversdorf, Ravindra Kashyap, Parth Mehta, Borna Mehrad, Ali Ataya, Jorge Lascano, Mark Brantly, Adam Austin, Eduard Koman, Thomas Galski, Vijaya Kumar, Ayman Soubani, Nicolas Harrison, Vineet Reddy, and Audrey Fonkam

Subjects
Venous Thrombosis, Treatment Outcome, Critical Illness, Physiology (medical), Humans, COVID-19, Anticoagulants, Thrombosis, Hemorrhage, Cardiology and Cardiovascular Medicine, Platelet Aggregation Inhibitors, Clopidogrel
Abstract

Background: The efficacy and safety of prophylactic full-dose anticoagulation and antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID-PACT (Prevention of Arteriovenous Thrombotic Events in Critically-ill COVID-19 Patients Trial) was a multicenter, 2×2 factorial, open-label, randomized-controlled trial with blinded end point adjudication in intensive care unit–level patients with COVID-19. Patients were randomly assigned to a strategy of full-dose anticoagulation or standard-dose prophylactic anticoagulation. Absent an indication for antiplatelet therapy, patients were additionally randomly assigned to either clopidogrel or no antiplatelet therapy. The primary efficacy outcome was the hierarchical composite of death attributable to venous or arterial thrombosis, pulmonary embolism, clinically evident deep venous thrombosis, type 1 myocardial infarction, ischemic stroke, systemic embolic event or acute limb ischemia, or clinically silent deep venous thrombosis, through hospital discharge or 28 days. The primary efficacy analyses included an unmatched win ratio and time-to-first event analysis while patients were on treatment. The primary safety outcome was fatal or life-threatening bleeding. The secondary safety outcome was moderate to severe bleeding. Recruitment was stopped early in March 2022 (≈50% planned recruitment) because of waning intensive care unit–level COVID-19 rates. Results: At 34 centers in the United States, 390 patients were randomly assigned between anticoagulation strategies and 292 between antiplatelet strategies (382 and 290 in the on-treatment analyses). At randomization, 99% of patients required advanced respiratory therapy, including 15% requiring invasive mechanical ventilation; 40% required invasive ventilation during hospitalization. Comparing anticoagulation strategies, a greater proportion of wins occurred with full-dose anticoagulation (12.3%) versus standard-dose prophylactic anticoagulation (6.4%; win ratio, 1.95 [95% CI, 1.08–3.55]; P =0.028). Results were consistent in time-to-event analysis for the primary efficacy end point (full-dose versus standard-dose incidence 19/191 [9.9%] versus 29/191 [15.2%]; hazard ratio, 0.56 [95% CI, 0.32–0.99]; P =0.046). The primary safety end point occurred in 4 (2.1%) on full dose and in 1 (0.5%) on standard dose ( P =0.19); the secondary safety end point occurred in 15 (7.9%) versus 1 (0.5%; P =0.002). There was no difference in all-cause mortality (hazard ratio, 0.91 [95% CI, 0.56–1.48]; P =0.70). There were no differences in the primary efficacy or safety end points with clopidogrel versus no antiplatelet therapy. Conclusions: In critically ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications with an increase in bleeding, driven primarily by transfusions in hemodynamically stable patients, and no apparent excess in mortality. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04409834.

Published
2022
Full Text
View/download PDF

32. Iron Deficiency in Heart Failure and Effect of Dapagliflozin

Author

Docherty, Kieran F., Welsh, Paul, Verma, Subodh, De Boer, Rudolf A., O'Meara, Eileen, Bengtsson, Olof, Køber, Lars, Kosiborod, Mikhail N., Hammarstedt, Ann, Langkilde, Anna Maria, Lindholm, Daniel, Little, Dustin J., Sjöstrand, Mikaela, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Morrow, David A., Schou, Morten, Solomon, Scott D., Sattar, Naveed, Jhund, Pardeep S., McMurray, John J.V., and Cardiovascular Centre (CVC)

Subjects
ferritin, heart failure, Stroke Volume, Iron Deficiencies, sodium-glucose cotransporter 2 inhibitor, anemia, iron, Glucosides, Hepcidins, Physiology (medical), Ferritins, Receptors, Transferrin, Receptors, Erythropoietin, Humans, Transferrins, transferrin, hepcidin, Benzhydryl Compounds, Cardiology and Cardiovascular Medicine, Biomarkers, erythropoiesis
Abstract

Background: Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We also analyzed the effect of dapagliflozin on outcomes, according to iron status at baseline. Methods: Iron deficiency was defined as a ferritin level Results: Of the 4744 patients randomized in DAPA-HF, 3009 had ferritin and transferrin saturation measurements available at baseline, and 1314 of these participants (43.7%) were iron deficient. The rate of the primary outcome was higher in patients with iron deficiency (16.6 per 100 person-years) compared with those without (10.4 per 100 person-years; P P -interaction=0.59). Similar findings were observed for cardiovascular death, heart failure hospitalization, and all-cause mortality. Transferrin saturation, ferritin, and hepcidin were reduced and total iron-binding capacity and soluble transferrin receptor increased with dapagliflozin compared with placebo. Conclusions: Iron deficiency was common in DAPA-HF and associated with worse outcomes. Dapagliflozin appeared to increase iron use but improved outcomes, irrespective of iron status at baseline. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03036124.

Published
2022
Full Text
View/download PDF

36. Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58

Author

Berg, David, Wiviott, Stephen D, RAZ, Itamar, Kamanu, Frederick, Im, KyungAh, Cahn, Avivit, Mosenzon, ofri, Bhatt, Deepak L, Jarolim, Petr, Leiter, Lawrence A, McGuire, Darren K, WILDING, JOHN, Huo, Yong, Lopez-sendon, Jose L, Ardissino, Diego, Gause-nilsson, Ingrid A, Sabatine, Marc S, and Morrow, David A

Published
2020
Full Text
View/download PDF

37. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58

Author

Zelniker, Thomas A, Morrow, David A, Mosenzon, ofri, Goodrich, Erica, Jarolim, Petr, Cahn, Avivit, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, WILDING, JOHN, Averkov, Oleg V, Budaj, Andrzej, Parkhomenko, Alexander, Ray, Kausik K, Gause-nilsson, Ingrid A, Langkilde, Anna Maria, Fredriksson, Martin, RAZ, Itamar, Sabatine, Marc S, and Wiviott, Stephen D

Published
2020
Full Text
View/download PDF

38. Abstract 15559: In-hospital versus Out-of-hospital Cardiac Arrest in Patients Presenting to Cardiac Intensive Care Units: From the Critical Care Cardiology Trials Network (CCCTN) Registry

Author

CARNICELLI, Anthony P, Brown, Kelly, Guo, Jianping, Kendsersky, Payton, Arps, Kelly E, Dixson, Jeffrey A, Keane, Ryan, Berg, David D, Bohula, Erin A, Harrison, Robert W, Granger, Christopher B, Van Diepen, Sean, Morrow, David A, Katz, Jason N, and Newby, L. Kristin

Published
2020
Full Text
View/download PDF

46. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

Author

Ern Yeoh, Su, primary, Docherty, Kieran F., additional, Campbell, Ross T., additional, Jhund, Pardeep S., additional, Hammarstedt, Ann, additional, Heerspink, Hiddo J.L., additional, Jarolim, Petr, additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Martinez, Felipe A., additional, Ponikowski, Piotr, additional, Solomon, Scott D., additional, Sjöstrand, Mikaela, additional, Bengtsson, Olof, additional, Greasley, Peter J., additional, Sattar, Naveed, additional, Welsh, Paul, additional, Sabatine, Marc S., additional, Morrow, David A., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

47. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

Author

Su Ern Yeoh, Kieran F. Docherty, Ross T. Campbell, Pardeep S. Jhund, Ann Hammarstedt, Hiddo J.L. Heerspink, Petr Jarolim, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Piotr Ponikowski, Scott D. Solomon, Mikaela Sjöstrand, Olof Bengtsson, Peter J. Greasley, Naveed Sattar, Paul Welsh, Marc S. Sabatine, David A. Morrow, and John J.V. McMurray

Subjects
Physiology (medical), Cardiology and Cardiovascular Medicine
Abstract

BACKGROUND: ET-1 (endothelin-1) is implicated in the pathophysiology of heart failure and renal disease. Its prognostic importance and relationship with kidney function in patients with heart failure with reduced ejection fraction receiving contemporary treatment are uncertain. We investigated these and the efficacy of dapagliflozin according to ET-1 level in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure). METHODS: We investigated the incidence of the primary outcome (cardiovascular death or worsening heart failure), change in kidney function, and the effect of dapagliflozin according to baseline ET-1 concentration, adjusting in Cox models for other recognized prognostic variables in heart failure including NT-proBNP (N-terminal pro-B-type natriuretic peptide). We also examined the effect of dapagliflozin on ET-1 level. RESULTS: Overall, 3048 participants had baseline ET-1 measurements of: tertile 1 (T1; ≤3.28 pg/mL; n=1016); T2 (>3.28–4.41 pg/mL; n=1022); and T3 (>4.41 pg/mL; n=1010). Patients with higher ET-1 were more likely male, more likely obese, and had lower left ventricular ejection fraction, lower estimated glomerular filtration rate, worse functional status, and higher NT-proBNP and hs-TnT (high-sensitivity troponin-T). In the adjusted Cox models, higher baseline ET-1 was independently associated with worse outcomes and steeper decline in kidney function (adjusted hazard ratio for primary outcome of 1.95 [95% CI, 1.53–2.50] for T3 and 1.36 [95% CI, 1.06–1.75] for T2; both versus T1; estimated glomerular filtration rate slope: T3, –3.19 [95% CI, –3.66 to –2.72] mL/min/1.73 m 2 /y, T2, –2.08 [95% CI, –2.52 to –1.63] and T1 –2.35 [95% CI, –2.79 to –1.91]; P =0.002). The benefit of dapagliflozin was consistent regardless of baseline ET-1, and the placebo-corrected decrease in ET-1 with dapagliflozin was 0.13 pg/mL (95% CI, 0.25–0.01; P =0.029). CONCLUSIONS: Higher baseline ET-1 concentration was independently associated with worse clinical outcomes and more rapid decline in kidney function. The benefit of dapagliflozin was consistent across the range of ET-1 concentrations measured, and treatment with dapagliflozin led to a small decrease in serum ET-1 concentration. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03036124.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results